2011/12/27 Taipei, Dec. 27, 2011 (CENS)--Seven new drugs developed in Taiwan have been approved by the Food and Drug Administration (FDA) of the United States for third-stage clinical trials, and some of them may be commercialized in 2012, said Wong Chi-huey, president of Taiwan's highest-level national research body Academia Sinica, at the 2011 Safety and Quality (SNQ) Award ceremony in Taipei, who added that over the next two to three years Taiwan`s biotechnology industry will grow explosively. Taiwan`s biotechnology line is globally recognized, and besides the said seven new drugs in third-stage trials, as many as 60 Taiwan-developed drugs now are in first- or second-stage trials, said Wong. In 2012, Wong stressed, several new drugs will be commercialized to mark a new milestone for Taiwan`s biotech industry as well as show the island`s strength to the whole world. According to Wong, biotech is an industry relevant to health, beauty and innovation, so players in the field have to be devoted for a long period to bear fruit. In the past 20 to 30 years or so, he added, the biotech industry in Taiwan has faced many challenges, including even misunderstanding due to politicking, but all adverse factors will be overcome.
No comments:
Post a Comment